Can venetoclax treat acute myeloid leukemia?

Venetoclax does have certain efficacy in the treatment of acute myeloid leukemia. It is an orally absorbable small molecule inhibitor of BCL-2. Its unique mechanism of action enables it to kill tumor cells that overexpress BCL-2 protein. In the treatment of acute myeloid leukemia, venetoclax can restore the apoptosis process of tumor cells by binding to BCL-2 protein, thereby helping to control disease progression.

Especially for those patients who are not suitable for intensive induction chemotherapy due to comorbidities, or for adults with newly diagnosed acute myeloid leukemia who are aged 75 years and above, the combination of venetoclax and azacitidine has become an effective treatment option. This combination therapy can significantly improve patients' survival and quality of life, providing a new treatment option for these specific patient groups.

However, venetoclax is not guaranteed to be effective in all patients with acute myeloid leukemia, and its effectiveness varies among individuals. At the same time, the use of venetoclax may also be associated with some side effects, such as gastrointestinal reactions, allergic reactions, etc., so it needs to be used under the guidance of a professional physician and the patient's reaction must be closely monitored.

In addition, the administration method and dosage of venetoclax are also key factors in the treatment process. According to the guidance of clinical studies, the dosage regimen of venetoclax usually includes a dose escalation period to ensure that patients can receive drug treatment safely and effectively.

Overall, venetoclax may serve as an effective treatment for acute myeloid leukemia, particularly in certain patient groups. However, its efficacy and safety need to be evaluated and monitored under the guidance of professional physicians to ensure that patients can obtain the best treatment results.